Form 8-K - Current report:
SEC Accession No. 0000950170-24-104428
Filing Date
2024-09-06
Accepted
2024-09-06 17:07:02
Documents
92
Period of Report
2024-09-06
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K aktx-20240906.htm   iXBRL 8-K 402005
2 EX-23.1 aktx-ex23_1.htm EX-23.1 4220
3 EX-99.1 aktx-ex99_1.htm   iXBRL EX-99.1 1664236
4 EX-99.2 aktx-ex99_2.htm   iXBRL EX-99.2 1272041
5 EX-99.3 aktx-ex99_3.htm EX-99.3 675351
  Complete submission text file 0000950170-24-104428.txt   18228855

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT aktx-20240906.xsd EX-101.SCH 2401350
94 EXTRACTED XBRL INSTANCE DOCUMENT aktx-20240906_htm.xml XML 3724492
Mailing Address 22 BOSTON WHARF ROAD FL 7 BOSTON MA 02210
Business Address 22 BOSTON WHARF ROAD FL 7 BOSTON MA 02210 (646) 350-0702
Akari Therapeutics Plc (Filer) CIK: 0001541157 (see all company filings)

EIN.: 981034922 | State of Incorp.: X0
Type: 8-K | Act: 34 | File No.: 001-36288 | Film No.: 241285178
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)